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Abstract
Solid tumors often develop an acidic environment due to the Warburg Effect. The effectiveness of
diagnosis and therapy may therefore be enhanced by the design and use of pH-sensitive agents that
target acidic tumors. Recently, a novel technology was introduced to target acidic tumors using
pHLIP (pH Low Insertion Peptide), a peptide that inserts across cell membranes as an α-helix when
the extracellular pH is acidic. In this study we expanded the application of the pHLIP technology to
include positron emission tomography (PET) imaging of the acidic environment in prostate tumors
using 64Cu conjugated to the pHLIP peptide (64Cu-DOTA-pHLIP). Studies demonstrated that this
construct avidly accumulated in LNCaP and PC-3 tumors, with higher uptake and retention in the
LNCaP tumors. Uptake correlated with differences in the bulk extracellular pH (pHe) of PC-3 and
LNCaP tumors measured in MR spectroscopy experiments by the 31P chemical shift of the
extracellular pH marker 3-aminopropylphosphonate. This manuscript introduces a novel class of
non-invasive pH-selective PET imaging agents and opens new research directions in the diagnosis
of acidic solid tumors.
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Introduction
Studies of the gene signatures of cancer cells indicate that many different genes are either up-
or down-regulated, even within a given type of tumor, so it is problematic to rely on any single
biomarker for the diagnosis of even a single type of cancer (1). However, physiological
processes (e.g., hypoxia and acidity), which are present in 90% of tumor microenvironments,
are considered promising environmental markers for tumor targeting (2,3). In particular, an
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acidic tumor environment plays a significant role in tumor progression and is often associated
with increased invasion and metastasis (4–6) as well as resistance to drug therapies (5,7,8).
Recently, a correlation was observed between extracellular pH (pHe) and overall survival
following treatment with combined hyperthermia and radiation therapy for spontaneous
sarcomas in canines (9). Tumor pH has practical importance because most anticancer drugs
must be transported either by active transport or by passive diffusion into cells, where they
frequently undergo further metabolism. As all of these processes might be pH sensitive, the
cytotoxic activity of an anticancer drug could depend on both the intracellular pH (pHi) and
the pHe. In the case of chemotherapeutic agents that are weak acids or bases and enter targeted
cells via passive diffusion, it is the non-ionized form that crosses the cell membrane. It also
has been suggested that modulation of tumor pH, both pHi and pHe, could be used to increase
the uptake of therapeutic drugs (7,10–12). Delineation of pHi from pHe is impossible with
electrode-based techniques due to the scale of the electrode compared to the tissue. Thus, non-
invasive tools for monitoring pHe and the effectiveness of its modulation could be extremely
valuable.
A number of MR-based methods for the estimation of pHe in animal tumor models have been
introduced in recent years. These approaches include use of T1-weighted MRI with
extracellular contrast agents that exhibit pH-dependent 1H relaxation enhancement (13), 1H
and 31P pH-dependent chemical shift measurements of exogenous extracellular species (14–
16), and 13C chemical shift imaging of hyperpolarized 13C-labeled bicarbonate (17). Studies
with the 31P extracellular pH indicator 3-aminopropylphosphonate (3-APP) have confirmed
that the average pHe of tumors is acidic, with values reaching as low as 6.0 (18). At present,
however, these techniques cannot be readily translated to the clinic.
Positron emission tomography (PET) is a widely used molecular imaging modality both in
clinical and research settings (19). The use of 64Cu as a PET nuclide, and the basis for new
radiopharmaceuticals, is particularly attractive given its 12.74 h half life (20). 64Cu-complexes
have been studied as PET agents with the nuclide incorporated into either small molecules or
peptides (21,22). Here we present the 64Cu PET imaging of prostate tumors using the recently
discovered acid-targeting peptide – pHLIP (pH Low Insertion Peptide) (23–25). The pHLIP
peptide contains 37 residues. At neutral extracellular pH, it interacts with the surface of
membranes as an unstructured peptide, but at acidic pHe (<7.0) it inserts across the membrane
and forms a stable transmembrane α-helix (24). We have shown that pHLIP can target a variety
of fluorescent dyes conjugated to its N-terminus to a tissue with elevated extracellular acidity
in vivo, and also that it can deliver chemotherapeutics into cells through interactions with the
membrane lipid bilayer, avoiding the need for any specific interaction with membrane proteins
(23,25,26). The present study was undertaken to evaluate whether it is possible to delineate
lower pHe in prostate tumors in vivo with 64Cu conjugated to the pHLIP peptide (64Cu-DOTA-
pHLIP), the first compound of a new generation of novel pH-selective tumor PET imaging
agents.
Materials and Methods
All chemicals, unless otherwise stated, were purchased from Sigma-Aldrich Chemical
Company, Inc (St. Louis, MO). Radioactive samples were counted in a radioisotope calibrator
(Capintec, Inc., Ramsey, NJ) for determination of mCi and an automated-well Beckman 8000
gamma counter (Beckman Coulter, Fullerton, CA) for counts per minute. Male athymic nu/nu
mice were purchased from the National Cancer Institute (Frederick, MD). Human prostate
carcinoma tumor cell lines PC-3 and LNCaP were obtained from American Type Culture
Collection (Manassas, VA) and maintained by serial passage in cell culture.
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Preparation of peptides and 64Cu radiolabeling
All peptides were prepared by solid-phase peptide synthesis using standard Fmoc (9-
fluorenylmethyloxycarbonyl) chemistry and purified by reverse phase chromatography (on a
C18 column) at the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale
University. Peptide sequences were:
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTG (pHLIP) and,
ACEQNPIYWARYAKWLFTTPLLLLKLALLVDADEGTG (K-pHLIP). The N-terminus of
the pHLIP peptide was covalently conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7-tris-
acetic acid-10-maleimidoethylacetamide, a maleimide-containing derivative of DOTA - a
chelator used for the effective binding of copper radionuclides (27). The peptides were
incubated with 2X molar excess of DOTA-maleimide (Macrocyclics Inc.) in the presence of
2 mM EDTA in PBS buffer pH 7.4 overnight, at 4°C. Free DOTA-maleimide and EDTA were
removed by a Sephadex G-10 spin column equilibrated with PBS buffer, pH 7.4. The
concentration of peptide was determined by absorbance at 280 nm using a molar extinction
coefficient of ε280=13,940 M−1cm−1. The composition and degree of conjugation were
confirmed by mass spectrometry and HPLC. The peptides were analyzed by electrospray mass
spectrometry (ES+) (DOTA-pHLIP: m/z calcd for C215H323N50O66S (M+) = 4693.3, found
1174.74 (M+4H+) and 1565.4 (M+3H+)). Reversed phase HPLC involved a Waters X-Bridge
(C4, 4.6 × 75 mm) column with a gradient (0 – 2 min 20%B to 40%B; 2 – 7 min 40%B to 70%
B; 7 – 10 min 70%B to 100%B (solvent A: 0.01% TFA in water; solvent B: 0.01% TFA in
acetonitrile) at a flow rate of 1 mL/min. Detection was accomplished at 280 nm and the retention
times for DOTA-pHLIP and DOTA-K-pHLIP were 5.45 and 4.82 min, respectively. The
peptides were stored at −80°C.
64Cu was produced at Washington University School of Medicine and processed by previously
reported literature methods (28). Maximal labeling for both constructs was achieved in 0.5 M
ammonium acetate buffer pH 5.5 at 25°C for 30 minutes at a ratio of 1:1 (μg:mCi). Prior to
purification, 5 mM of EDTA was added to scavenge any uncomplexed 64Cu. Purification was
achieved by C18 SepPak Light using 100% ethanol as the eluent. Purity and labeling efficiency
were determined by radio-TLC on silica using 10% ammonium acetate:methanol (50:50).
Acute biodistribution
All animal experiments were performed in compliance with the Guidelines for the Care and
Use of Research Animals established by Washington University’s Animal Studies Committee.
20–25 g male athymic mice (NCI) were implanted in the right flank with either 1 × 107 PC-3
or LNCaP human prostate adenocarcinoma cells in 100 μL cell media with >90% viability.
The LNCaP cells were implanted using Matrigel (BD Biosciences, San Jose, CA). Tumors
were allowed to grow to approximately 0.5 – 0.75 cm3 in volume. Mice were randomized prior
to the study. To investigate specific uptake of tumor, organ, and other non-target tissues, a
small amount of 64Cu-DOTA-pHLIP (~28 μCi, 0.22 μg) was injected intravenously into each
of the mice bearing palpable PC-3 or LNCaP tumors. The animals were sacrificed at selected
time points after injection (1, 4, 24, and 48 hours; n = 4–5) and desired tissues were removed,
weighed, and counted for radioactivity accumulation. The percentage injected dose per gram
(%ID/g) and percentage injected dose per organ (%ID/organ) were calculated by comparison
to a weighed, counted standard solution. An additional group of PC-3 mice were injected
with 64Cu-DOTA-K-pHLIP (~28 μCi, 0.22 μg) and were sacrificed at 1 h (n = 5). Due to a
technical error an additional group of mice were injected and just the kidneys were removed.
Since the aspartic acid residues have been changed to lysines in the transmembrane portion,
the K-pHLIP peptide should not have the ability to form an α-helix and span the membrane of
the cells in acidic environments. On a different day, an additional cohort of LNCaP-bearing
mice (which were implanted with a different passage of LNCaP cells, n = 8) were split into
two groups, with the first group receiving 150 mM bicarbonated water at pH 8.0 (3.1455 g of
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sodium bicarbonate, dissolved in 250 mL drinking water) ad libitum for 7 days prior to the
acute biodistribution study (4 h) to modulate tumor pHe (12,25,29) and the second group
receiving regular drinking water. MRS studies were performed on the tumors in all of these
mice prior to biodistribution.
Small Animal PET
Imaging 64Cu-DOTA-pHLIP was performed on two tumor models using a microPET-F220
(30). Imaging was performed in 10-minute static sessions, with a collection of 600 frames per
session. Isoflurane (2%) was used as an inhaled anesthetic to induce and maintain anesthesia
during imaging. Male athymic mice implanted in the right flank with PC-3 (n = 4) or LNCaP
(n = 10) human prostate adenocarcinoma cells which were allowed to grow until palpable. At
this point, the mice were injected IV with 200 μCi 64Cu-DOTA-pHLIP and were then imaged
in pairs at 1, 4, and 24 hours post injection. Images were reconstructed by Fourier rebinning
followed by two-dimensional Ordered Subset Expectation Maximization (OSEM). Small
animal PET images were evaluated by analysis of the standardized uptake value (SUV) of the
tumor and muscle using the software ASIPRO (Concorde MicroSystems, Inc.). The average
radioactivity concentration within the tumor or tissue was obtained from the average pixel
values reported in nCi/cc within a volume of interest (VOI) drawn around the entire tumor or
tissue on multiple, consecutive transaxial image slices. SUVs were calculated by dividing this
value, the decay-corrected activity per unit volume of tissue (nCi/mL), by the injected activity
per unit of body weight (nCi/g).
Magnetic Resonance Spectroscopy
In vivo extracellular pHe was determined in LNCaP and PC3 tumors within the 24-hour period
immediately prior to injection of 64Cu-labeled pHLIP peptides. Non-invasive measurements
of pHe were based on the 31P MR-observable chemical shift of 3-aminopropylphosphonate (3-
APP) (31). Prior to MR measurements, mice bearing PC-3 (n = 3) or LNCaP (n = 6) tumors
were anesthetized with isoflurane and were maintained on isoflurane/O2 (1.25 % v/v)
throughout data collection. Each anesthetized mouse received an i.p. injection of 0.35 mL of
3-APP (Sigma-Aldrich, St. Louis, MO) solution prepared at a concentration of 75 mg 3-APP/
mL in isotonic saline. After injection, mice were placed in a head holder with a nose cone for
delivery of anesthetic gas and a custom-built 31P MR surface coil was placed around the tumor.
31P MR studies were performed using a small-animal MR scanner based on a Magnex Scientific
Instruments (Oxford, UK) 11.74 tesla (31P resonance frequency 202.3 MHz), 26-cm
horizontal-bore magnet interfaced with a Varian NMR Systems (Palo Alto, CA) INOVA
console. Magnetic field homogeneity was optimized by shimming on the free induction decay
of the tumor water resonance, observed through the 31P MR surface coil. 31P spectral
acquisition parameters were: sweep width of 20,000 Hz, 0.3 s acquisition time, 4.06 s repetition
time and a 60° excitation pulse. A total of 512 transients were averaged for each measurement;
thus, the total length of each 31P scan was 34 minutes. MR data were processed with a matched
filter (30 Hz line-broadening) and frequency estimates for the 31P MR spectral components
were performed using a Bayesian Probability Theory analysis package developed at
Washington University (32). The resulting estimated chemical-shift difference between 3-APP
and the pH-independent α-nucleoside triphosphate (α-NTP) resonance (33) was used to
determine extracellular pH based on the fitting parameters provided by Gillies, et al (31).
Statistics
Statistically significant differences between mean values were determined using analysis of
variance (ANOVA) coupled to Scheffe’s test or, for statistical classification, a Student’s t-test
was performed. Differences at the 95% confidence level (P < 0.05) were considered significant.
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Results
64Cu-DOTA-pHLIP and 64Cu-DOTA-K-pHLIP can be obtained in high yield and good specific
activity
64Cu labeling of DOTA-pHLIP was attempted at various pH values between 4.5 and 9.2 using
0.125–0.2 M ammonium acetate. Optimal labeling was achieved in 0.5 M ammonium acetate
buffer pH 5.5 at 25°C for 30 minutes at a ratio of 1:1 (μg:mCi) at a specific activity of 1591
mCi/μmol. Without heating, the labeled solution remained stable overnight. Radiochemical
purity was consistently >95% following EDTA scavenge and SepPak purification, as shown
by radio-TLC on silica using 10% ammonium acetate:methanol (50:50). As a control, we used
a mutant version of pHLIP (K-pHLIP) in which key Asp residues of the transmembrane part
of pHLIP were replaced by positively charged Lys residues (Figure 1). These changes prevent
the peptide from inserting across the cell membrane and forming an α-helix at acidic pH.(25)
The mutant/control peptide (K-pHLIP) was labeled in a similar manner at a specific activity
of 1713 mCi/μmol at >95% radiochemical purity.
Acute biodistribution of 64Cu-DOTA-pHLIP in PC3 and LNCaP, and 64Cu-DOTA-K-pHLIP in
PC-3 tumor bearing mice
Organ, tissue and tumor uptake was examined by acute biodistribution studies of 64Cu-DOTA-
pHLIP after injection into male nude mice bearing either LNCaP or PC-3 tumors (Table 1).
One additional group of PC-3 bearing mice received the equivalent mass of 64Cu-DOTA-K-
pHLIP as a control. The PC-3 tumor accumulation of 64Cu-DOTA-pHLIP reached a maximum
after 4 h (2.78 ± 0.19 %ID/g) and the tumor retention was high, with 2.46 ± 0.57 %ID/g
remaining at 24 h. In the LNCaP mice, tumor accumulation of 64Cu-DOTA-pHLIP reached a
maximum after only 1 h (4.50 ± 1.71 %ID/g) and the tumor retention was also high, with 3.23
± 0.55 %ID/g remaining at 24 h and 1.74 ± 1.41 %ID/g at 48 post-injection. The biodistribution
data for 64Cu-DOTA-pHLIP showed that the radioactive background in the blood and blood-
rich organs, such as liver, lung, heart and spleen, were similar in the two tumor models while
differences were noted in the tumors. Examination of tumor-to-tissue ratios (Figure 2) clearly
shows that, for imaging purposes, the 4 h timepoint is optimal for both tumor models. This can
be attributed to the better retention of the agent in tumor tissue and the more rapid washout of
activity from background organs.
The administration of the mutant peptide, 64Cu-DOTA-K-pHLIP, resulted in a ~40% lower
PC-3 tumor accumulation at 1 h post-injection which is impressive in that the subsequent MRS
study showed the PC-3 tumors to be less acidic. However, distribution of the control
peptide, 64Cu-DOTA-K-pHLIP, was similar in pattern to the parent, 64Cu-DOTA-pHLIP,
although with a reduction in accumulation in all tissues. The most likely reason for this
universal reduction is a more rapid excretion of the mutant-pHLIP, which has been observed
by fluorescence imaging as well, and, as a consequence, less retention in the blood and therefore
the tissues. Our biophysical studies indicate that pHLIP binds to the surfaces of membranes at
normal pH (26), which might lead to the slow kinetics of peptide distribution in vivo. Most
probably, the mutant pHLIP has reduced binding affinity to the membrane, and, therefore, a
faster kinetic profile. It is important to note that the mutant peptide was not taken up to the
same extent by the skin or the kidney, which are tissues known to be more acidic than all other
healthy tissues and organs.
The final groups of animals studied were LNCaP-bearing mice that were given either normal
drinking water or water spiked with sodium bicarbonate to modulate the tumor pHe. As shown
by MRS, the bicarbonate water resulted in the modulated tumor having a more basic pHe (vide
infra). The results of the biodistribution in these mice (Table 2) were similar to those for LNCaP
tumors presented in Table 1, but it is important to note that these studies were performed on
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different dates with mice that had been implanted with a different passage of LNCaP cells.
Except for uptake in the tumor and kidney, no significant differences were observed between
the two groups in the 17 collected organs and tissues. 64Cu-DOTA-pHLIP uptake in the non-
modulated LnCAP tumors was greater than the uptake in the tumors in mice that received 7
days of bicarbonated water (4.50 ± 1.71 vs. 1.31 ± 0.60, respectively, P = 0.005).
Small Animal PET Imaging of 64Cu-DOTA-pHLIP in PC3 and LNCaP prostate tumors
Delineation of the tumor by uptake of 64Cu-DOTA-pHLIP was evident in both tumor models
(Figure 3) but to a greater extent in the LNCaP bearing mice, while 64Cu-DOTA-K-pHLIP did
not exhibit any targeting ability (data not shown). In the PC-3 model, the tumor to muscle ratios
derived from the SUV values for uptake of native peptide at 1, 4, and 24 hours were 1.45 ±
0.09, 2.67 ± 0.40, and 4.64 ± 1.08, showing a gradual increase in tumor uptake with concurrent
washout from non-target organs. The tumor to muscle ratios derived from the SUV values in
the LNCaP tumor model were significantly higher (P = 0.0001), with values of 3.44 ± 0.50,
5.56 ± 0.21 and 6.55 ± 1.98 for the 1, 4 and 24 hour time points, respectively.
MRS directly measures the volume-average pHe of tumors
The acute biodistribution data and imaging results presented above demonstrate higher uptake
and retention of 64Cu-DOTA-pHLIP in the non-alkalinized LNCaP tumors, and suggest that
the extracellular pH of LNCaP tumors is more acidic than that of PC-3 tumors. To determine
tumor-average pHe directly, 31P MR spectroscopy measurements with the exogenous
extracellular pH marker 3-APP were used (Figure 4). PC-3 and LNCaP tumor models were
selected for pH measurements based on their significantly different SUV values as measured
by PET, with LNCaP showing more uptake of the pHLIP peptide than PC-3. This difference
was mirrored in the pH values determined by MR, with the LNCaP tumors showing a
significantly more acidic average pHe (6.78 ± 0.29) when compared to the PC-3 tumors (7.23
± 0.10) (P = 0.039). Additional evidence that the 64Cu-DOTA-pHLIP targeted pHe was
provided in the study in LNCaP tumors in which half of the mice were fed bicarbonated water
prior to the biodistribution. As expected, in this experiment the average pHe in the non-
modulated LnCAP tumors was more acidic than the average pHe of the tumors in mice having
received 7 days of bicarbonated water (6.62 ± 0.35 vs. 6.94 ± 0.56, respectively P = 0.28). This
correlates well with the data from the biodistribution where 64Cu-DOTA-pHLIP uptake in the
non-modulated LnCAP tumors was greater that the uptake in the tumors in mice having
received 7 days of bicarbonated water (4.50 ± 1.71 vs. 1.31 ± 0.60, respectively, P = 0.005).
It should also be noted that the pHe measured in our MRS experiments is a volume-averaged
pHe. Although this measured pHe provides a good indication of the acidity outside of the cell,
it may not reflect the exact pH on the exterior surface of the cells and does not account for
tumor heterogeneity. Thus, pHe as measured by MRS is an indicator, but not a direct measure,
of the pH causing insertion.
Discussion
The physiological differences between normal and tumor tissues provide an opportunity for
the development of novel diagnostic and therapeutic agents specifically targeting cancer cells.
However, the acidic extracellular environment in tumors has not been properly exploited,
probably due to a lack of compounds whose properties change dramatically in the range of pH
6.0–7.5. The significance of the current work is that it proposes an innovative and novel method
to target tumors based on an intrinsic physiological property - the acidic extracellular
environment, and thereby addresses an important problem in the diagnosis and monitoring or
response to therapy of cancer. The method is based on the pH-selective interaction of the pHLIP
peptide with cell membranes. In this study, we have demonstrated and validated a novel, pH-
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selective PET tracer - 64Cu-DOTA-pHLIP. This is the first time a peptide-based PET agent
has been employed for the delineation of the pHe of tumors.
Our data show that 64Cu-DOTA-pHLIP is stable in tumors. None of the animals in any of the
studies showed any adverse effects due to the administration of any of the pHLIP constructs.
The biodistribution and PET imaging data demonstrated retention of radioactivity in the tumors
over 24 h. The tumor uptake of 64Cu-DOTA-pHLIP correlates well with in vivo fluorescence
imaging studies, which demonstrated that Cy5.5-pHLIP and Alexa750-pHLIP stayed in tumors
for several (>4) days (25). This long retention might be explained by the fact that when the
peptide is inserted into the cell membrane it is protected from attack by proteases, allowing it
to accumulate in tumor tissue in significant amounts.
There are two main factors that might contribute to the accumulation of pHLIP peptides in
non-tumor tissue. While at normal, physiological pH the probability of pHLIP insertion into
the cell membrane is low, the peptide still interacts with the surface of the membrane through
its hydrophobic motif. Although this produces a small background signal, it also allows for a
longer blood circulation of pHLIP, enhancing the probability of delivering functional imaging
moieties or therapeutic cargo to the site of disease. The background signal decreases with time,
while the signal in tumors remains static or is enhanced. A second reason for unwanted
background is the relative instability of the 64Cu-DOTA chelation. 64Cu has been shown to
dissociate in vivo from DOTA and DOTA-conjugates, undergoing subsequent metabolism and
trans-chelation to superoxide dismutase and other proteins, resulting in increased accumulation
in the blood and liver (27,34,35). This could account, in part, for the main differences in
biodistribution between Cy5-pHLIP and 64Cu-DOTA-pHLIP, particularly the difference in
liver uptake. In contrast to the PET results, the fluorescence data showed a very low uptake of
Cy5.5-pHLIP by the liver (25), since the NIR dyes were conjugated covalently to the N-
terminus of the peptide. We therefore believe that the apparent liver uptake of 64Cu-DOTA-
pHLIP could be significantly decreased by optimizing the copper-chelating moiety. The cross-
bridged cyclam chelator, CBTE2A, has demonstrated improved in vivo stability and
consequently a reduction in transchelation (35,36), but requires elevated temperatures for
copper complexation that may not compatible with the pHLIP peptide construct.
The control peptide, 64Cu-DOTA-K-pHLIP, which had just two amino acid residues replaced,
demonstrated ~40% less PC-3 tumor uptake as early as 1 hour post-injection; we did anticipated
that the mutant peptide would have lower uptake in the PC-3 model (the less acidic tumor)
than the parent pHLIP. Also, small-animal PET imaging experiments showed that control
peptide did not accumulate in tumors, consistent with previous fluorescence studies (25). Also
we observed lowering of K-pHLIP level in blood and tissues, even though the equivalent mass
of labeled K-pHLIP was administered and the data is normalized to the injected dose (%ID/
g). We assume that rapid excretion of the mutant-pHLIP could be associated with its reduced
affinity to the membrane at normal pH, in contrast to the parent pHLIP. Our thermodynamic
studies indicated that pHLIP has high affinity to the membrane at normal pH (ΔGbinding is
about −7 kcal/mol at 37°C) (26), which is probably associated with the prolongated peptide
circulation in the blood. The pHLIP affinity to the cell membrane increases in an environment
of low pH, at which point pHLIP inserts into the membrane and adopts a stable transmembrane
configuration. In contrast to pHLIP, the mutant peptide K-pHLIP cannot insert into the cell
membrane to form a transmembrane alpha-helix (25), so it can be assumed that the tumor
uptake we observed for 64Cu-DOTA-K-pHLIP in the acute biodistribution studies must be due
to the passive diffusion of the construct into the tumor interstitium. Also, as stated, we cannot
exclude the possibility that the creation of 64Cu bound to serum proteins by exchange
with 64Cu-DOTA-pHLIP contributes to the background, especially at early time points.
Therefore, even though it is known that K-pHLIP does not target acidity the use of K-pHLIP
may not be an appropriate control system.
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The selectivity of the pHLIP peptide was demonstrated by the modulation of pHe in LNCaP-
bearing mice in which more acidic LNCaP tumors had greater uptake of 64Cu-DOTA-pHLIP
than the less-acidic (bicarb-modulated) LNCaP tumors. As can be seen from Table 2, it is clear
that administering sodium bicarbonate significantly altered the uptake of the peptide only in
the tumor and kidney. Unlike with k-pHLIP (Table 1) there were no significant differences in
the uptake by the skin, which cannot be explained at this time. The use of bicarbonate is known
to have a profound effect on pHe.(12,25,29) For example, Raghunand et al, showed with 31P-
magnetic resonance spectroscopy (MRS) that the pHe of MCF-7 human breast cancer
xenografts can be effectively and significantly raised with sodium bicarbonate in drinking
water.(12) This was achieved with the mice drinking ad libitum water containing 200 mM
NaHCO3 for periods up to 90 days continuously, without any changes in subjective parameters
and weight gain compared to control mice. In this current study the average pHe in the non-
modulated LnCaP tumors was more acidic than the average pHe of the tumors in mice having
received 7 days of bicarbonated water (6.62 ± 0.35 vs. 6.94 ± 0.56, respectively p = 0.28). This
correlated well with the data from the acute biodistribution where 64Cu-DOTA-pHLIP uptake
in the non-modulated LnCaP tumors was significantly greater that the uptake in the tumors in
mice having received 7 days of bicarbonated water (4.50 ± 1.71 vs. 1.31 ± 0.60, respectively,
p = 0.005).
Apart from the liver and blood uptake, the quantitative PET data and images are in general
agreement with the biodistribution studies and the previous reported fluorescence studies
(25), including uptake of the peptide by the kidney. The kidney has acidic regions and is a
major site of catabolism of low-molecular-weight proteins. The kidney uptake can be reduced
by providing mice with bicarbonate-buffered drinking water at pH 8.0 (12,25,29), or drugs like
acetozalomide, a carbonic anhydrase inhibitor that causes urinary alkalization. This reduction
in kidney uptake with bicarbonate-buffered drinking water was confirmed in our own study
presented in Table 2.
In summary, we have synthesized and evaluated the first generation of novel pHe sensitive
peptide PET agents for the delineation of low pHe in tumors. This is the first report of this
novel class of PET imaging agents. Although the biokinetics of the agent are not optimal,
additional strategies are currently under development to enhance tumor accumulation while
reducing unwanted background uptake. This first generation agent offers the possibility of
designing a new class of non-invasive pH-selective PET imaging agents that will be useful for
the imaging of a broad range of disease states. Multimodal (diagnostic + therapeutic) pHLIP
peptides with an N-terminus imaging label and C-terminus chemotherapeutic cargo (23) would
afford the opportunity to monitor drug delivery, providing a key tool in efforts to predict
therapeutic outcome.
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Figure 1.
Amino acid sequence of the native peptide compared to the mutant pHLIP (K-pHLIP).
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Figure 2.
Comparisons of various tumor-to-tissue ratios from 64Cu-DOTA-pHLIP biodistribution data
presented in Table 1. Tumor %ID/g was divided by the corresponding %ID/g of the tissue of
interest for (a) blood (b) liver (c) kidney and (d) muscle. *Denotes statistical significance at
the 95% confidence level (P < 0.05).
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Figure 3.
Representative small-animal PET image slices of 64Cu-DOTA-pHLIP (200 μCi per animal)
in LNCaP (measured tumor pHe = 6.78 ± 0.29) and PC-3 (measured tumor pHe = 7.23 ± 0.10)
tumor-bearing mice at various post- injection time points. Differences in tumor SUV values
can be visualized by comparing the LNCaP (a) coronal and (b) transaxial slices to the PC-3 (c)
transaxial and (d) coronal slices. In each image, the tumor is denoted by a white circle.
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Figure 4. In vivo
31P MR spectrum of a PC-3 tumor. Extracellular pH is estimated from the chemical shift
difference (in ppm) between the extracellular pH indicator 3-APP and the pH-independent
chemical shift of α-NTP. The scale bar above the 3-APP resonance indicates a range of
chemical shifts (δ) from 24.0 to 26.0 ppm, corresponding to the physiologic range of pHe (6.17
– 7.43).
V vere et al. Page 14
Cancer Res. Author manuscript; available in PMC 2010 May 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
V vere et al. Page 15
Table 1
Acute biodistribution of 64Cu-DOTA-pHLIP in tissues in PC-3 and LNCaP mice and 64Cu-DOTA-K-pHLIP in PC-3
mice.
PC-3 1 hour Cu-64-DOTA-pHLIP 4 hour Cu-64-DOTA-pHLIP 24 hour Cu-64-DOTA-pHLIP 1 hour Cu-64-DOTA-K-pHLIP
blood 11.27 ± 0.81 7.45 ± 1.76 2.59 ± 0.48 7.09 ± 0.67
lung 5.16 ± 0.51 4.25 ± 0.94 2.35 ± 0.46 3.75 ± 0.18
liver 8.56 ± 1.14 7.99 ± 1.28 5.86 ± 1.23 5.21 ± 1.75
spleen 2.10 ± 0.14 2.02 ± 0.47 1.82 ± 0.44 1.64 ± 0.29
kidney 6.32 ± 0.39 6.93 ± 0.83 4.64 ± 1.27 4.63 ± 0.35*
muscle 1.11 ± 0.79 0.86 ± 0.16 0.65 ± 0.14 0.56 ± 0.09
skin 1.77 ± 0.09 2.07 ± 0.36 1.87 ± 0.33 0.96 ± 0.06
fat 0.80 ± 0.39 0.86 ± 0.27 0.53 ± 0.18 1.09 ± 0.80
heart 3.95 ± 0.60 3.17 ± 0.83 1.67 ± 0.14 2.50 ± 0.55
brain 0.47 ± 0.11 0.35 ± 0.12 0.16 ± 0.04 0.30 ± 0.06
bone 1.55 ± 0.19 1.17 ± 0.41 0.81 ± 0.14 1.12 ± 0.41
PC-3 1.72 ± 0.17 2.78 ± 0.19 2.46 ± 0.57 1.04 ± 0.15
LNCaP 1 hour Cu-64-DOTA-pHLIP 4 hour Cu-64-DOTA-pHLIP 24 hour Cu-64-DOTA-pHLIP 48 hour Cu-64-DOTA-pHLIP
blood 14.97 ± 1.11 8.08 ± 0.35 3.96 ± 1.11 1.68 ± 0.35
lung 5.63 ± 0.62 4.38 ± 0.39 3.22 ± 0.53 2.22 ± 0.70
liver 6.53 ± 1.02 4.80 ± 0.72 4.88 ± 0.98 4.43 ± 0.74
spleen 2.75 ± 0.48 2.05 ± 0.09 1.84 ± 0.27 1.41 ± 0.35
kidney 8.34 ± 0.66 5.42 ± 0.58 4.48 ± 1.08 2.76 ± 0.50
muscle 1.38 ± 0.53 0.72 ± 0.11 0.85 ± 0.25 0.49 ± 0.10
skin 4.16 ± 1.72 2.35 ± 0.15 2.87 ± 0.54 1.68 ± 0.20
fat 2.40 ± 0.73 0.87 ± 0.17 0.60 ± 0.16 0.26 ± 0.14
heart 5.31 ± 1.03 3.60 ± 0.28 2.02 ± 0.31 1.45 ± 0.08
brain 0.45 ± 0.06 0.29 ± 0.05 0.24 ± 0.05 0.16 ± 0.04
bone 3.77 ± 1.88 1.03 ± 0.10 1.00 ± 0.28 0.60 ± 0.10
LNCaP 4.50 ± 1.71 3.67 ± 0.56 3.23 ± 0.55 1.74 ± 1.41
*
Due to a technical error an additional group of mice were used to produce this data. Data presented as the percent injected dose per gram of tissue ±
standard deviation (%ID/g ± SD) in n = 4–5 mice per group.
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Table 2
Acute biodistribution in LNCaP-bearing mice split into two groups, (1) mice received 150 mM bicarbonated water at
pH 8.0 ad libitum for 7 days prior the study, and (2) mice were fed regular drinking water. Data presented as the percent
injected dose per gram of tissue ± standard deviation (%ID/g ± SD) in n = 4 mice per group.
4 hour (untreated) 4 hour (modulated)
blood 7.21 ± 1.39 7.27 ± 1.00
lung 3.63 ± 0.63 3.85 ± 0.61
liver 5.29 ± 1.64 5.79 ± 0.66
spleen 1.49 ± 0.32 1.53 ± 0.25
kidney* 5.20 ± 1.06 3.78 ± 0.29
muscle 0.69 ± 0.40 1.05 ± 0.80
skin 1.12 ± 0.29 1.02 ± 0.27
fat 1.26 ± 1.42 1.16 ± 0.50
heart 2.07 ± 0.28 2.39 ± 0.44
brain 0.59 ± 0.69 0.27 ± 0.06
bone 1.22 ± 1.15 2.22 ± 2.51
pancreas 1.48 ± 0.77 1.56 ± 0.67
stomach 0.88 ± 0.58 1.01 ± 0.26
small int 2.05 ± 1.04 2.48 ± 0.59
upper lg int 2.35 ± 1.25 3.55 ± 1.94
lower lg int 1.28 ± 0.79 1.23 ± 0.54
LNCaP* 4.50 ± 1.71 1.31 ± 0.60
*
Denotes statistical significance (P < 0.005) between the treated and non-treated groups. (lg int = large intestine)
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